Healthcare tech company Omnicell (NASDAQ:OMCL) reported Q4 CY2024 results , with sales up 18.6% year on year to $306.9 ...

Benchmark analysts maintained a Buy rating on Omnicell stock (NASDAQ:OMCL) with a consistent price target of $62.00 as the company approaches its earnings release scheduled for February 6. The target ...

Omnicell reported Q4 2024 revenues of $307 ... Allen Lutz, Bank of America: Asked about hospital budget growth and product revenue ramp. CEO Lipps responded, "Improved financial conditions of ...

Here at Omnicell, we are entering 2025 with a renewed ... Thanks, Allen, for the questions. Yes, I think the hospital financial conditions and providers have continued to improve.

OMNICELL ($OMCL) posted quarterly earnings results on Thursday, February 6th. The company reported earnings of $0.60 per share, beating estimates of $0.59 by $0.01 ...

For the current quarter ending in March, Omnicell expects its per-share earnings to range from 15 cents to 25 cents. The company said it expects revenue in the range of $255 million to $265 ...

Healthcare tech company Omnicell (NASDAQ:OMCL ... However, headwinds such as tightening hospital budgets, cybersecurity threats, and the fragmented nature of healthcare systems could slow adoption.